How Each Compound Works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the endogenous GLP-1 hormone, which is released from intestinal L-cells after eating. Binding the GLP-1 receptor stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system pathways. Semaglutide's half-life of roughly one week, achieved through fatty-acid side-chain modifications and albumin binding, allows once-weekly subcutaneous injection or daily oral dosing in the approved pharmaceutical forms.

Retatrutide operates on three receptors at once: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Adding GIP agonism is thought to amplify the appetite-suppressing and metabolic effects beyond what GLP-1 alone produces. The glucagon receptor component is the most novel piece; glucagon typically raises blood glucose, but at the doses used in retatrutide research, glucagon receptor activation appears to increase energy expenditure and promote fat oxidation in the liver. Whether that three-way mechanism translates to a meaningfully different safety or efficacy profile in large, long-term trials remains an open question.

The Evidence Base for Semaglutide

Semaglutide has one of the deepest evidence bases of any peptide-derived compound in clinical use. The SUSTAIN program, a series of Phase 3 randomized controlled trials published between 2016 and 2019 across journals including The New England Journal of Medicine and The Lancet Diabetes and Endocrinology, enrolled thousands of participants with type 2 diabetes and demonstrated consistent HbA1c reductions and modest weight loss. The STEP program then focused specifically on obesity: STEP 1, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults without diabetes and found that participants receiving 2.4 mg weekly semaglutide lost a mean of 14.9 percent of body weight over 68 weeks versus 2.4 percent for placebo.

Cardiovascular outcome data also exist. The SELECT trial, results published in the New England Journal of Medicine in November 2023, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease. Participants receiving semaglutide showed a 20 percent relative risk reduction in major adverse cardiovascular events compared to placebo over a mean follow-up of 34 months. That kind of large, long-duration, hard-endpoint trial is rare for any peptide-related compound and sets semaglutide apart from nearly everything else in this category.

The FDA approved subcutaneous semaglutide as Ozempic (for type 2 diabetes, 2017) and as Wegovy (for chronic weight management, 2021). Oral semaglutide is approved as Rybelsus for type 2 diabetes. Research-chemical semaglutide sold by peptide vendors is not any of these approved products and carries none of their regulatory standing.

The Evidence Base for Retatrutide

Retatrutide's published human data comes primarily from a single Phase 2 dose-ranging trial, results published in the New England Journal of Medicine in June 2023. The trial enrolled 338 adults with obesity but without diabetes across multiple dose groups. At the highest dose tested, participants lost a mean of 24.2 percent of body weight over 48 weeks, a figure that exceeded anything previously reported in a randomized trial of a weight-loss agent. The trial was randomized and placebo-controlled, which places it above animal or in-vitro work, but Phase 2 trials are designed to assess preliminary efficacy and tolerability, not to confirm safety and efficacy at the population level.

The most common adverse events in that Phase 2 trial were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the GLP-1 class broadly. Discontinuation rates due to adverse events were higher in the higher-dose groups. No cardiovascular outcome data, no long-term safety data, and no data in patients with established cardiovascular disease have been published for retatrutide as of mid-2025. Phase 3 trials are underway, registered on ClinicalTrials.gov, but results have not been reported.

Retatrutide has no FDA approval and no approved branded pharmaceutical form. It is an investigational compound. Any retatrutide available from research-chemical vendors is not an approved drug and has not completed the regulatory review process.

How Do the Weight-Loss Numbers Compare Directly?

Direct head-to-head randomized trials comparing semaglutide and retatrutide in the same population do not exist in the published literature as of mid-2025. Comparing across separate trials is methodologically imperfect because populations, trial durations, inclusion criteria, and baseline characteristics differ. With that caveat stated plainly: the STEP 1 trial reported roughly 15 percent mean body weight loss with semaglutide 2.4 mg over 68 weeks; the retatrutide Phase 2 trial reported up to 24 percent mean body weight loss at the highest dose over 48 weeks. The retatrutide figure comes from a smaller trial with a shorter follow-up and no long-term safety data.

Tirzepatide, the dual GLP-1/GIP agonist approved as Mounjaro and Zepbound, sits between the two in terms of published weight-loss data, with the SURMOUNT-1 trial reporting up to 22.5 percent mean body weight loss. Retatrutide adds glucagon receptor agonism on top of that dual mechanism, which may explain the incremental difference in the Phase 2 numbers, though confirming that mechanistic explanation requires larger trials. The practical implication for researchers is that retatrutide's numbers are striking but rest on a much thinner evidence base than semaglutide's.

Regulatory Status and What It Means for Research Use

Semaglutide's approved pharmaceutical forms (Ozempic, Wegovy, Rybelsus) have passed FDA review for specific indications, meaning the agency has evaluated manufacturing quality, clinical trial data, and labeling. Those approvals apply to those specific branded products made by Novo Nordisk. Compounded semaglutide from 503B outsourcing facilities has had a complicated regulatory history, with the FDA updating its shortage-list status for semaglutide in 2024 and 2025 in ways that affect what compounders can legally produce. Research-chemical semaglutide from peptide vendors operates outside all of that framework.

Retatrutide has no approved form at all. It is in active clinical development by Eli Lilly. Phase 3 trials registered on ClinicalTrials.gov include studies in obesity and type 2 diabetes. Until those trials complete and the FDA reviews a New Drug Application, retatrutide remains an investigational compound with no legal pathway to prescription use in the United States. Vendors selling retatrutide as a research chemical are selling a compound with Phase 2 human data and no regulatory clearance.

For anyone evaluating vendor claims about either compound, the regulatory gap between semaglutide and retatrutide is significant. Semaglutide has a reference standard in the form of approved drugs; retatrutide does not. Purity and identity verification through third-party certificates of analysis matter for both, but the absence of any approved retatrutide product means there is no pharmaceutical benchmark to compare against.